The new COVID-19 antibody treatment, Bamlanivimab, is now being used for qualified patients at Kettering Health Network.
Earlier this month, the Food and Drug Administration gave emergency use authorization of the antibody Bamlanivimab. Patients may be eligible for the infusion treatment if they are suffering from moderate symptoms of COVID-19 including, but not limited to
Based on results in clinical trials, this treatment helps prevent hospital admissions or trips to the emergency department and reduce the risk of disease progression.
"This is another tool in our arsenal against COVID-19. By using Bamlanivimab, we hope to help more patients avoid hospital stays," says Jeffrey Weinstein, MD, patient safety officer for Kettering Health Network. "We will continue to seek the latest advancements to ensure that the people of southwest Ohio have access to the best possible care."
A physician referral is needed for this treatment, and primary care or emergency department providers will determine if a patient qualifies.